Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study.

Jernberg T, Lindholm D, Hasvold LP, Svennblad B, Bodegård J, Sundell Andersson K, Thuresson M, Erlinge D, Janzon M.

BMJ Open. 2019 Apr 3;9(4):e027199. doi: 10.1136/bmjopen-2018-027199.

2.

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.

Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW.

Endocrinol Diabetes Metab. 2018 Aug 31;1(4):e00036. doi: 10.1002/edm2.36. eCollection 2018 Oct.

3.

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.

Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW.

Diabetes Obes Metab. 2019 May;21(5):1136-1145. doi: 10.1111/dom.13627. Epub 2019 Feb 6.

PMID:
30609272
4.

Change in Cardiorespiratory Fitness and Risk of Stroke and Death.

Prestgaard E, Mariampillai J, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen S, Grundvold I, Berge E.

Stroke. 2018 Dec 10:STROKEAHA118021798. doi: 10.1161/STROKEAHA.118.021798. [Epub ahead of print]

PMID:
30580727
5.

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.

Birkeland KI, Bodegard J, Norhammar A, Kuiper JG, Georgiado E, Beekman-Hendriks WL, Thuresson M, Pignot M, Herings RMC, Kooy A.

Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13612. [Epub ahead of print]

PMID:
30537226
6.

SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up.

Mariampillai JE, Prestgaard EE, Kjeldsen SE, Liestøl K, Engeseth K, Erikssen J, Bodegard J, Berge E, Grundvold I, Skretteberg PT.

J Hypertens. 2019 May;37(5):949-955. doi: 10.1097/HJH.0000000000001959.

PMID:
30325341
7.

Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men.

Engeseth K, Prestgaard EE, Mariampillai JE, Grundvold I, Liestol K, Kjeldsen SE, Bodegard J, Erikssen JE, Gjesdal K, Skretteberg PT.

Eur J Prev Cardiol. 2018 Oct;25(15):1655-1663. doi: 10.1177/2047487318793459. Epub 2018 Aug 14.

PMID:
30103630
8.

Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men.

Farkhooy A, Bodegård J, Erikssen JE, Janson C, Hedenström H, Stavem K, Malinovschi A.

BMC Pulm Med. 2018 Jul 18;18(1):118. doi: 10.1186/s12890-018-0655-z.

9.

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.

10.

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group.

Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. No abstract available.

PMID:
29784708
11.

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Nyström T, Bodegård J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW.

Diabetes Care. 2018 Jun;41(6):e104-e105. doi: 10.2337/dc18-0339. No abstract available.

PMID:
29784707
12.

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014.

Nathanson D, Sabale U, Eriksson JW, Nyström T, Norhammar A, Olsson U, Bodegård J.

Pharmacoecon Open. 2018 Dec;2(4):393-402. doi: 10.1007/s41669-017-0063-y.

13.

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17.

14.

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.

15.

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. No abstract available.

PMID:
29483180
16.

Long-term predictors of stroke in healthy middle-aged men.

Prestgaard E, Hodnesdal C, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen SE, Grundvold I, Berge E.

Int J Stroke. 2018 Apr;13(3):292-300. doi: 10.1177/1747493017730760. Epub 2017 Sep 20.

PMID:
28929941
17.

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.

PMID:
28781064
18.

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.

Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI.

Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8.

19.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*.

Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.

20.

Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden.

Sabale U, Bodegard J, Svennblad B, Östgren CJ, Johansson G, Ekman M, Henriksson M, Nilsson P.

Prim Care Diabetes. 2017 Jun;11(3):217-225. doi: 10.1016/j.pcd.2017.03.001.

Supplemental Content

Loading ...
Support Center